SLC30A5 and prostate carcinoma: This could imply that ZnT-5 deficiency may potentially have serious compound consequences in bone health in men treated with androgen deprivation therapies (ADTs or hormone therapies) used to treat advanced prostate cancer and are known to affect bone stability [97,98].